LAVAL, QUEBEC--(Marketwire - July 21, 2010) - Warnex Inc. (TSX:WNX), the Montreal Heart Institute (MHI) and CEPMED (The Centre of Excellence in Personalized Medicine) are collaborating to develop a new diagnostic test for early detection of cardiovascular and metabolic diseases. It is hoped that this test will enable more personalized treatment of diseases such as atherosclerosis and diabetes. Financed in part by CEPMED, the test will be developed by Warnex in collaboration with Dr. Éric Thorin, a researcher at the MHI.
"Warnex is pleased to collaborate with these organizations with the objective of contributing to the advancement of personalized medicine in the cardiovascular field," said Mark Busgang, President and CEO of Warnex. "Warnex is well positioned to help researchers commercialize new diagnostic tools by developing and validating innovative assays based on their findings."
The diagnostic test to be developed is an enzyme-linked immunosorbent assay (ELISA) for detecting angiopoietin-like protein 2 (Angptl2) in blood. Angptl2 stimulates the formation of new blood vessels, provokes inflammation and is elevated in the blood of patients with cardiovascular disease.
"This is a highly stimulating project that could give rise to complementary research projects and therefore help to advance research on cardiovascular diseases," said Dr. Thorin.
"This collaboration is a good example of CEPMED's capacity to bring together researchers and companies for purposes of promoting the development of new tools in personalized medicine," said Clarissa Desjardins, CEO of CEPMED.
About the Montreal Heart Institute
Founded in 1954 by Dr. Paul David, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in prevention, ultra-specialized care, professionals training, clinical and fundamental research, and assessment of new technologies. The Institute is part of a vast network of excellence in health formed by the Université de Montréal and its affiliated institutions. To learn more about the Institute, please visit our website at www.icm-mhi.org.
About the Center of Excellence in Personalized Medicine (CEPMED)
CEPMED is a non-profit organization dedicated to promoting the science and practice of personalized medicine through research, commercialization and education. It currently participates in several multi-million dollar public-private partnerships in translational medicine that incorporate pharmacogenetic testing into Phase III clinical trials and studies of marketed products. In addition, it funds strategic personalized medicine research projects with high commercialization potential. Founded by the Montreal Heart Institute, it is a Centre of Excellence for Commercialization and Research (CECR) supported by the Canadian Government, Genome Quebec as well as private partners including Pfizer, AstraZeneca, Novartis and Merck.
Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex Analytical Services provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex Bioanalytical Services specializes in bioequivalence and bioavailability studies for clinical trials. Warnex Medical Laboratories provides specialized testing for the healthcare industry as well as pharmaceutical and central laboratory services. Warnex PRO-DNA Services offers DNA identification tests for paternity, maternity and other family relationships, as well as for immigration and forensic testing purposes. Warnex has three facilities located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.